Immune Microenvironment and Gene Expression Profiling in Mesothelioma

Launched by ISTITUTO ONCOLOGICO VENETO IRCCS · Aug 29, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the immune environment and gene expression in patients with pleural and peritoneal mesothelioma, which are rare cancers often linked to asbestos exposure. The aim is to better classify different subgroups of mesothelioma, which could lead to personalized treatment options for patients. Researchers will collect and analyze tumor samples from 220 participants in Italy, both from those currently undergoing treatment and those who have completed their treatment. This study hopes to identify new targets for therapy that may improve outcomes for patients with this challenging disease.

To be eligible for this trial, participants must be over 18 years old and have a confirmed diagnosis of pleural or peritoneal mesothelioma. They should have received active cancer treatment and be at least six months post-treatment. Patients who have had surgeries will need both biopsy and surgical samples. It's important to know that the study is currently recruiting participants, and those who join can expect to provide tumor samples for detailed analysis, which may help in the development of more effective treatments for mesothelioma in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with Mesothelioma of the Pleura and Peritoneum
• • Age greater than 18 years of age
• • Patients undergoing surgery will require both biopsy and surgical sampling material
• • Pathologist's confirmation of the presence of tumor sections in the excised specimens
• • Patients in follow-up from active cancer treatment for at least 6 months
• Exclusion Criteria:
• • Inadequacy of biological material for analysis under study
• • Patients not amenable to active oncologic treatment
• • Patients lost to follow-up before 6 months after the end of active oncologic treatment